Abstract 5053
Background
Colorectal mucinous carcinoma (MAC) is a distinct subtype of colorectal carcinoma (CRC) accounting for approximately 10-20% of all CRCs. Mucinous carcinomas characterized by the presence of abundant extracellular mucin which occupies at least 50% of the tumour volume. Patients are often diagnosed at an advanced stage in young patients showing a poor prognosis with the 3-year overall survival rate of 57%. Although clinicopathologic findings of colorectal MACs are relatively well known, their molecular alterations have not elucidated. We investigate molecular alterations of colorectal MACs revealed by next-generation sequencing (NGS).
Methods
We retrospectively reviewed cases of CRCs with mucinous component and 111 MACs subject to molecular profiling using NGS on the Ion Proton (Thermo Fisher Scientific). We examined substitutions and small indels in 409 cancer-related genes using Ion ampliseq Cancer Hotspot and Ion ampliseq Comprehensive Cancer panels.
Results
Of the 111 patients included in the analysis, 60 (54.1%) were male: the median age was 58 years. BRAF was mutated in 17% of colorectal MACs (19 of 111) and 9.0% of CRCs (18 of 200), V600E mutations were predominantly identified in MACs, representing 95% (18 of 19) of BRAF mutated cases (p = 0.0438). GNAS mutations were frequently detected in 14.4% of colorectal MACs (19 of 111) and 1.5% of CRC (3 of 200), R201C and R201H were more commonly mutated, representing 95% (18 of 19) of GNAS mutated cases (p < 0.001). SMAD4 mutations were frequently noted in colorectal MACs compared with those of CRCs (24 of 111 vs. 22 of 200, p = 0.0187).
Conclusions
This study demonstrates distinct genomic differences in colorectal MACs compare with CRCs. The genomic profiling of colorectal MACs revealed by NGS can identify potentially targetable molecular alterations in the majority of colorectal MACs (95.5%). Overall, colorectal MACs harbor relatively high frequencies of BRAF, GNAS, and SMAD4 mutations compared with those of CRCs. This distinct activating or inactivating mutations of these genes suggest promising consideration of targeted therapy by inhibiting related pathways in patients with advanced colorectal MACs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Mi Lee.
Funding
Jeju National University Hospital.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1025 - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging.
Presenter: Angela Lamarca
Session: Poster Display session 2
Resources:
Abstract
5813 - Is MGMT methylation a new therapeutic target for Biliary Tract Cancer?
Presenter: Monica Niger
Session: Poster Display session 2
Resources:
Abstract
5839 - Biliary Tract Cancers in Portuguese families with BRCA gene mutation: a retrospective study.
Presenter: Patricia Pereira
Session: Poster Display session 2
Resources:
Abstract
4338 - Selection of patients with hepatocellular carcinoma for selective internal radiation therapy based on tumour burden and liver function: a post-hoc analysis of the SARAH trial
Presenter: Daniel Palmer
Session: Poster Display session 2
Resources:
Abstract
1700 - Second-line chemotherapy (SLC) in Patients with Advanced Biliary tract and Gallbladder Cancers (ABGC) Prolongs Survival: A Retrospective Population-based Cohort Study
Presenter: Adnan Zaidi
Session: Poster Display session 2
Resources:
Abstract
5562 - Overall survival of patients with hepatocellular carcinoma receiving sorafenib versus selective internal radiation therapy with predicted dosimetry in the SARAH trial
Presenter: Neil Hawkins
Session: Poster Display session 2
Resources:
Abstract
1838 - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
Presenter: Naohiro Okano
Session: Poster Display session 2
Resources:
Abstract
3641 - Soluble Programmed Death-ligand 1 indicate poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization
Presenter: Xiaolu Ma
Session: Poster Display session 2
Resources:
Abstract
2733 - The Prognostic Nutritional Index (PNI) is an independent predictor of survival in advanced biliary cancers (ABC) receiving first-line chemotherapy (1L).
Presenter: Francesco Caputo
Session: Poster Display session 2
Resources:
Abstract
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract